Compare MTW & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | RGNX |
|---|---|---|
| Founded | 1902 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 528.6M |
| IPO Year | 1994 | 2015 |
| Metric | MTW | RGNX |
|---|---|---|
| Price | $12.87 | $14.19 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.50 | ★ $28.75 |
| AVG Volume (30 Days) | 275.8K | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,240,900,000.00 | $10,393,000.00 |
| Revenue This Year | $4.73 | $51.21 |
| Revenue Next Year | $2.98 | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.89 | ★ 126.48 |
| 52 Week Low | $9.09 | $5.46 |
| 52 Week High | $15.56 | $16.19 |
| Indicator | MTW | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 71.59 |
| Support Level | $12.28 | $10.34 |
| Resistance Level | $13.42 | $15.81 |
| Average True Range (ATR) | 0.57 | 1.29 |
| MACD | -0.13 | 0.45 |
| Stochastic Oscillator | 33.99 | 78.75 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.